JP2006521335A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006521335A5 JP2006521335A5 JP2006505892A JP2006505892A JP2006521335A5 JP 2006521335 A5 JP2006521335 A5 JP 2006521335A5 JP 2006505892 A JP2006505892 A JP 2006505892A JP 2006505892 A JP2006505892 A JP 2006505892A JP 2006521335 A5 JP2006521335 A5 JP 2006521335A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- compound according
- hydrocarbyl
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 73
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 19
- 108010087999 Steryl-Sulfatase Proteins 0.000 claims 15
- 102100038021 Steryl-sulfatase Human genes 0.000 claims 15
- 230000006907 apoptotic process Effects 0.000 claims 11
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical group NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 claims 11
- 102000005262 Sulfatase Human genes 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 9
- 230000005764 inhibitory process Effects 0.000 claims 9
- 108060007951 sulfatase Proteins 0.000 claims 9
- -1 hydrocarbyl compound Chemical class 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 230000022131 cell cycle Effects 0.000 claims 7
- 230000004190 glucose uptake Effects 0.000 claims 7
- 230000005747 tumor angiogenesis Effects 0.000 claims 7
- 230000004663 cell proliferation Effects 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 125000000565 sulfonamide group Chemical group 0.000 claims 5
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims 5
- 102000029749 Microtubule Human genes 0.000 claims 4
- 108091022875 Microtubule Proteins 0.000 claims 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 210000004688 microtubule Anatomy 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 102000003390 tumor necrosis factor Human genes 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 125000002560 nitrile group Chemical group 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 150000003431 steroids Chemical group 0.000 claims 3
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 230000033228 biological regulation Effects 0.000 claims 2
- 230000008512 biological response Effects 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 2
- 230000025915 regulation of apoptotic process Effects 0.000 claims 2
- 230000025053 regulation of cell proliferation Effects 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims 1
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 1
- 101150065749 Churc1 gene Proteins 0.000 claims 1
- 102100038239 Protein Churchill Human genes 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 125000002009 alkene group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 230000002939 deleterious effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 229960003399 estrone Drugs 0.000 claims 1
- 125000001033 ether group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000006882 induction of apoptosis Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 0 C*(CCC1CC2)CC1C(CC1)C2C2C1C*CCC2 Chemical compound C*(CCC1CC2)CC1C(CC1)C2C2C1C*CCC2 0.000 description 5
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0306717.0 | 2003-03-24 | ||
| GB0306717A GB0306717D0 (en) | 2003-03-24 | 2003-03-24 | Compound |
| GB0315885A GB0315885D0 (en) | 2003-07-07 | 2003-07-07 | Compound |
| GB0315885.4 | 2003-07-07 | ||
| PCT/GB2004/000705 WO2004085459A1 (en) | 2003-03-24 | 2004-02-20 | Oestrogen derivatives as inhibitors of steroid sulphatase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006521335A JP2006521335A (ja) | 2006-09-21 |
| JP2006521335A5 true JP2006521335A5 (https=) | 2007-03-01 |
| JP4719144B2 JP4719144B2 (ja) | 2011-07-06 |
Family
ID=33099976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006505892A Expired - Fee Related JP4719144B2 (ja) | 2003-03-24 | 2004-02-20 | ステロイドスルファターゼのインヒビターとしてのエストロゲン誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7893284B2 (https=) |
| EP (1) | EP1608671B1 (https=) |
| JP (1) | JP4719144B2 (https=) |
| AT (1) | ATE454395T1 (https=) |
| AU (1) | AU2004224053B2 (https=) |
| BR (1) | BRPI0408703A (https=) |
| CA (1) | CA2520142C (https=) |
| DE (1) | DE602004024966D1 (https=) |
| DK (1) | DK1608671T3 (https=) |
| EA (1) | EA011123B1 (https=) |
| ES (1) | ES2339450T3 (https=) |
| MX (1) | MXPA05010339A (https=) |
| PL (1) | PL378577A1 (https=) |
| WO (1) | WO2004085459A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0113920D0 (en) | 2001-06-07 | 2001-08-01 | Sterix Ltd | Composition |
| US8030298B2 (en) | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| WO2008090517A2 (en) * | 2007-01-26 | 2008-07-31 | Piramal Life Sciences Limited | Enriched plant extract, compound, and methods for the treatment of proliferative disorders |
| EP2149371A1 (en) | 2008-07-28 | 2010-02-03 | PregLem S.A. | Use of steroid sulfatase inhibitors for the treatment of preterm labor |
| US20110190323A1 (en) * | 2008-08-28 | 2011-08-04 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses thereof |
| EP2421882A4 (en) * | 2009-04-22 | 2013-05-08 | Harvard College | ANGIOGENESIS INHIBITORS |
| US9388210B2 (en) | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| EP3572417B1 (en) | 2011-10-14 | 2025-12-17 | Sage Therapeutics, LLC | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| HUE039057T2 (hu) | 2012-12-18 | 2018-12-28 | Univ Washington | Kezelési eljárásokban alkalmazható neuroaktív 19-alkoxi-17-szubsztituált szteroidok |
| US9512170B2 (en) | 2013-03-01 | 2016-12-06 | Washington University | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors |
| US9365502B2 (en) | 2013-03-11 | 2016-06-14 | Washington University | Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors |
| US9562026B2 (en) | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| EP2986624B1 (en) | 2013-04-17 | 2020-03-25 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids for methods of treatment |
| SI3021852T1 (sl) | 2013-07-19 | 2021-07-30 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporabe le-teh |
| AU2014308621C1 (en) | 2013-08-23 | 2022-01-06 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| AU2014369834B2 (en) | 2013-12-24 | 2018-12-20 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ME03809B (me) | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a |
| CN117024501A (zh) | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| RS61530B1 (sr) | 2015-01-26 | 2021-04-29 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns |
| EP4155314A1 (en) | 2015-02-20 | 2023-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2016182932A1 (en) | 2015-05-08 | 2016-11-17 | President And Fellows Of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
| EP3316889A4 (en) | 2015-07-01 | 2018-11-14 | President and Fellows of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| JP6992748B2 (ja) * | 2016-06-15 | 2022-02-03 | ソニーグループ株式会社 | 情報処理装置、観察システム、観察方法及びプログラム |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| WO2018013615A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| SG11202112391UA (en) | 2019-05-31 | 2021-12-30 | Sage Therapeutics Inc | Neuroactive steroids and compositions thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4994439A (en) * | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
| DE19723794A1 (de) * | 1997-06-06 | 1998-12-10 | Jenapharm Gmbh | Nichtestrogene Derivate des Estradiols mit antioxidativer Aktivität |
| US6288050B1 (en) * | 1997-07-18 | 2001-09-11 | Duquesne University Of The Holy Ghost | Steroid sulfatase inhibitors and methods for making and using the same |
| GB2331987B (en) * | 1997-12-04 | 2002-11-27 | Imperial College | Polycyclic sulphamate inhibitors of oestrone sulphatase |
| US6046186A (en) * | 1997-12-24 | 2000-04-04 | Sri International | Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use |
| AU765386B2 (en) * | 1998-06-10 | 2003-09-18 | Sterix Limited | Pharmaceutical composition with tumor necrosis factor a and 2-methoxyestrone-3-(o)-sulphamate for inhibition of estrone sulphatase |
| JP5042411B2 (ja) * | 1999-04-30 | 2012-10-03 | ステリックス リミテッド | 抗腫瘍剤としてのエストロン誘導体の使用 |
| JPWO2001081364A1 (ja) * | 2000-04-24 | 2004-01-08 | 協和醗酵工業株式会社 | エストラ−１，３，５（１０）−トリエン誘導体 |
| DE60112438T2 (de) * | 2000-05-11 | 2006-06-08 | Research Institute For Medicine And Chemistry Inc., Cambridge | 2-substituirte pregna-1,3,5(10)-trien- und chola-1,3,5(10)-trien- derivate und ihre biologische aktivität |
| GB0020498D0 (en) * | 2000-08-18 | 2000-10-11 | Sterix Ltd | Compound |
| AU8494601A (en) * | 2000-08-18 | 2002-03-04 | Univ Illinois | Prodrugs of betulinic acid derivatives for the treatment of cancer and HIV |
| WO2002062347A1 (en) | 2001-02-05 | 2002-08-15 | Oncology Sciences Corporation | Method and composition of novel compounds for the therapy and targeting of the primary modalities of cancer cell proliferation and homeostasis |
| GB0421106D0 (en) * | 2004-09-22 | 2004-10-27 | Sterix Ltd | Compound |
-
2004
- 2004-02-20 PL PL378577A patent/PL378577A1/pl not_active Application Discontinuation
- 2004-02-20 AT AT04713124T patent/ATE454395T1/de not_active IP Right Cessation
- 2004-02-20 DE DE602004024966T patent/DE602004024966D1/de not_active Expired - Lifetime
- 2004-02-20 AU AU2004224053A patent/AU2004224053B2/en not_active Ceased
- 2004-02-20 WO PCT/GB2004/000705 patent/WO2004085459A1/en not_active Ceased
- 2004-02-20 MX MXPA05010339A patent/MXPA05010339A/es active IP Right Grant
- 2004-02-20 DK DK04713124.8T patent/DK1608671T3/da active
- 2004-02-20 BR BRPI0408703-8A patent/BRPI0408703A/pt not_active IP Right Cessation
- 2004-02-20 EP EP04713124A patent/EP1608671B1/en not_active Expired - Lifetime
- 2004-02-20 JP JP2006505892A patent/JP4719144B2/ja not_active Expired - Fee Related
- 2004-02-20 EA EA200501426A patent/EA011123B1/ru not_active IP Right Cessation
- 2004-02-20 CA CA2520142A patent/CA2520142C/en not_active Expired - Fee Related
- 2004-02-20 ES ES04713124T patent/ES2339450T3/es not_active Expired - Lifetime
-
2005
- 2005-09-23 US US11/233,945 patent/US7893284B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006521335A5 (https=) | ||
| CA2520142A1 (en) | Oestrogen derivatives as inhibitors of steroid sulphatase | |
| CN1091601C (zh) | 用苯酚取代的二磷酸酯作抗肿瘤剂 | |
| JP2009536191A5 (https=) | ||
| CN114072396A (zh) | 作为dna-pk抑制剂的喹啉和噌啉衍生物 | |
| JP7205830B2 (ja) | 新規アントラニル酸系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤 | |
| CN102596946A (zh) | 抗病毒化合物及其制备和使用方法 | |
| JP7302025B2 (ja) | 結腸・直腸がんを治療するための薬物の製造におけるｆｇｆ２１の使用 | |
| JP2023510746A5 (https=) | ||
| JP2004531478A5 (https=) | ||
| CA2434028A1 (en) | Amino ceramide-like compounds and therapeutic methods of use | |
| US6586461B1 (en) | Prenyl transferase inhibitors | |
| JP2002517449A5 (https=) | ||
| WO2018149231A1 (zh) | 7H-吡咯并[2,3-d]嘧啶衍生物及抗肿瘤的应用 | |
| JP7229482B2 (ja) | 新規アミド系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤 | |
| JPH06192201A (ja) | 置換フェノール、それらの製造方法および細胞増殖に起因する疾患の治療のためのそれらの使用 | |
| JPWO2019031471A1 (ja) | 脂肪性肝疾患の治療剤及び肥満症の治療剤 | |
| RU2008138165A (ru) | Стероидные соединения в качестве ингибиторов стероидсульфатазы | |
| CN115487177B (zh) | 一种黄酮类化合物用于治疗溃疡性结肠炎的新用途 | |
| CN101074189B (zh) | 苯乙烯酸衍生物及其在制备血管靶向剂药物中的应用 | |
| CN104262289B (zh) | 一种苯并噻唑衍生物及其抗肿瘤用途 | |
| CN106619628B (zh) | 苦参碱衍生物在制备预防或治疗绝经后骨质疏松症药物中的应用 | |
| WO2017034242A2 (ko) | 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물 | |
| WO2001032658A1 (en) | Polyazanaphthalene compound and medicinal use thereof | |
| CN101200465B (zh) | 一种十氢化萘类化合物及其医药用途 |